Prescription medication costs are forcing some hard choices for many Nevadans. Two years ago, a proposal that offered hope sailed through the Democrat-majority Nevada Legislature only to be vetoed ...

The agency has given a thumbs up to Sanofi’s Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk’s NovoLog for patients with diabetes. Insulin aspart is delivered by a ...

It calls the new drug “Merilog,” a biosimilar to the widely-used insulin product Novolog (insulin aspart). READ: Stem cells show promise in reversing type 1 diabetes The FDA defines a ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. “Merilog ...

Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...

The FDA has approved 65 biosimilar products to date. Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously ...

Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

Merilog administered subcutaneously 5 to 10 minutes before mealtime helps improve glycemic control. (HealthDay News) — The US Food and Drug Administration has approved Merilog (insulin-aspart ...